These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25378232)

  • 1. B-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1.
    Choi YW; Kim HJ; Kim YH; Park SH; Chwae YJ; Lee J; Soh EY; Kim JH; Park TJ
    Exp Mol Med; 2014 Nov; 46(11):e120. PubMed ID: 25378232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TSH signaling overcomes B-RafV600E-induced senescence in papillary thyroid carcinogenesis through regulation of DUSP6.
    Kim YH; Choi YW; Han JH; Lee J; Soh EY; Park SH; Kim JH; Park TJ
    Neoplasia; 2014 Dec; 16(12):1107-20. PubMed ID: 25499223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
    Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
    Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.
    Siraj AK; Pratheeshkumar P; Parvathareddy SK; Bu R; Masoodi T; Iqbal K; Al-Rasheed M; Al-Dayel F; Al-Sobhi SS; Alzahrani AS; Al-Dawish M; Al-Kuraya KS
    Eur J Cancer; 2019 Aug; 117():133-144. PubMed ID: 31280122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential regulation of the human sodium/iodide symporter gene promoter in papillary thyroid carcinoma cell lines and normal thyroid cells.
    Kogai T; Hershman JM; Motomura K; Endo T; Onaya T; Brent GA
    Endocrinology; 2001 Aug; 142(8):3369-79. PubMed ID: 11459780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.
    Dong H; Shen WZ; Yan YJ; Yi JL; Zhang L
    J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):77-81. PubMed ID: 26838744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NADPH Oxidase NOX4 Is a Critical Mediator of BRAF
    Azouzi N; Cailloux J; Cazarin JM; Knauf JA; Cracchiolo J; Al Ghuzlan A; Hartl D; Polak M; Carré A; El Mzibri M; Filali-Maltouf A; Al Bouzidi A; Schlumberger M; Fagin JA; Ameziane-El-Hassani R; Dupuy C
    Antioxid Redox Signal; 2017 May; 26(15):864-877. PubMed ID: 27401113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The correlation of sodium iodide symporter and BRAF(V600E) mutation in classical variant papillary thyroid carcinoma.
    Yazgan A; Yıldırım N; Gözalan A; Gümüştaş S; Kılıçarslan A; Balci S; Aydın C; Ersoy R; Cakir B; Güler G
    Ann Diagn Pathol; 2016 Jun; 22():58-62. PubMed ID: 27180062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypermethylation of a New Distal Sodium/Iodide Symporter (NIS) enhancer (NDE) is associated with reduced NIS expression in thyroid tumors.
    Galrão AL; Camargo RY; Friguglietti CU; Moraes L; Cerutti JM; Serrano-Nascimento C; Suzuki MF; Medeiros-Neto G; Rubio IG
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E944-52. PubMed ID: 24432988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
    Gao WL; Wie LL; Chao YG; Wie L; Song TL
    Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of correlation for sodium iodide symporter mRNA and protein expression and analysis of sodium iodide symporter promoter methylation in benign cold thyroid nodules.
    Neumann S; Schuchardt K; Reske A; Reske A; Emmrich P; Paschke R
    Thyroid; 2004 Feb; 14(2):99-111. PubMed ID: 15068624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and
    Tavares C; Eloy C; Melo M; Gaspar da Rocha A; Pestana A; Batista R; Bueno Ferreira L; Rios E; Sobrinho Simões M; Soares P
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FoxP3 in papillary thyroid carcinoma induces NIS repression through activation of the TGF-β1/Smad signaling pathway.
    Ma S; Wang Q; Ma X; Wu L; Guo F; Ji H; Liu F; Zhao Y; Qin G
    Tumour Biol; 2016 Jan; 37(1):989-98. PubMed ID: 26264613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
    Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
    Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.
    Mitsutake N; Miyagishi M; Mitsutake S; Akeno N; Mesa C; Knauf JA; Zhang L; Taira K; Fagin JA
    Endocrinology; 2006 Feb; 147(2):1014-9. PubMed ID: 16254036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
    Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
    Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered gene expression profiles by sodium/iodide symporter gene transfection in a human anaplastic thyroid carcinoma cell line using a radioactive complementary DNA microarray.
    Gol Choe J; Kim YR; Kim KN; Choo HJ; Shin JH; Lee YJ; Chung JK; Kim MK
    Nucl Med Commun; 2005 Dec; 26(12):1155-62. PubMed ID: 16264365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation levels of sodium-iodide symporter (NIS) promoter in benign and malignant thyroid tumors with reduced NIS expression.
    Galrão AL; Sodré AK; Camargo RY; Friguglietti CU; Kulcsar MA; Lima EU; Medeiros-Neto G; Rubio IG
    Endocrine; 2013 Feb; 43(1):225-9. PubMed ID: 22945693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.